TRCT
MPLT

Tower Research Capital (TRC)’s MapLight Therapeutics MPLT Stock Holding History

Tower Research Capital (TRC)’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$71.5K Buy
1,996
+68
+4% +$1.96K ﹤0.01% 2456
2026
Q1 		$39.2K Sell
1,928
-942
-33% -$16.9K ﹤0.01% 2961
2025
Q4 		$50.4K Buy
+2,870
New +$48.1K ﹤0.01% 2407

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Tower Research Capital (TRC)'s MPLT Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its MapLight Therapeutics (MPLT) stake by 3.5% in Q2 2026, buying an estimated $1.96K and bringing the position to 1,996 shares worth $71.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2456.

Tower Research Capital (TRC) first reported a position in MPLT in Q4 2025 and has held it in 3 quarters since. 105 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • Tower Research Capital (TRC) held 1,996 shares of MapLight Therapeutics worth $71.5K as of Q2 2026.
  • Tower Research Capital (TRC) bought 68 MapLight Therapeutics shares in Q2 2026, an estimated $1.96K.
  • MapLight Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2456 holding.
  • Tower Research Capital (TRC) first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 105 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.